Home | MannKind MNKD Message Board
3 天之前 · Discuss MannKind and its stock (news, fundamentals) 6,706: 174,794: CDSCO Approves Afrezza® (insulin human) Inhalation Powder in by agedhippie Dec 13, 2024 18:03:51 GMT -5: MNKD Product Script Counts and Other Metrics. This is the place for tabulation and commentary on the script counts formulary adoption, and other metrics. (Members Only) 134 ...
All About MNKD | MannKind MNKD Message Board - ProBoards
Message board for discussion of MNKD, MannKind Corporation. MannKind MNKD Message Board. Skip Navigation.
MannKind Successfully Completes Phase 1 Trial of Nintedanib
2024年11月4日 · MannKind’s nintedanib DPI Phase 1 has already shown what we hoped for which is a lack of the oral med side-effects which are so horrible patients would rather experience IPF than take Ofev. Assuming Phase II/III prove the rest that’s needed for approval by the FDA, who gets marketing rights can get worked out over time.
2024 upcoming catalysts | MannKind MNKD Message Board
2024年10月3日 · Message board for discussion of MNKD, MannKind Corporation. I assume they're referring to a balance sheet accounting for the amount of cash MannKind received from Sagard in return for MannKind assigning 10% of their 10% (net 1%) of royalties from United Therapeutics for sale of Tyvaso DPI that was developed and is manufactured by MannKind.
MNKD - 201 | MannKind MNKD Message Board
2024年11月7日 · Mannkind -- nintedanib. peppy Postaholic. Afrezza (Insulin human) Peaks in 35 mins Baseline 90 mins. Posts ...
MNKD - 201 | MannKind MNKD Message Board
2024年11月11日 · I don't know anything about anything with respect to MannKind's EBU, or prospects for development projects, selling a business unit, or being acquired, but the forward-looking statements seemed a little muted to me. Nothing about any other prospects in the pipeline (but perhaps too far out?). Very little said about Cipla or India, or debt ...
Is a MNKD buyout likely? | MannKind MNKD Message Board
2024年8月22日 · MannKind presented a slide in the 1Q EC that forecast >$7.5B in 2030 revenue for Ofev and the existing minor competitor product (Esbriet) with Ofev presumably accounting 90% of the revenue. With that kind of revenue at risk, B-I has to be developing a strategy on how to maintain that revenue leadership.
MannKind to Present at Upcoming Conferences
2024年8月27日 · DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Aug. 27, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of innovative inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, announced today that …
MannKind Receives U.S. FDA Fast Track Designation
2024年5月25日 · MannKind Receives U.S. FDA Fast Track Designation for Clofazimine Inhalation Suspension for the Treatment of Nontuberculous Mycobacterial (NTM) Lung Disease 05/06/24 DANBURY, Conn. and WES
Know what you own. [MNKD convertible bonds] | MannKind …
2024年10月31日 · Tyvaso DPI net sales need to double in 2 years for Mannkind to get that $50M (roughly). Given recent sales growth rates, IPF will need to be approved and be marketed to hit those #'s Q3 2024 Net product sales for Tyvaso DPI were $274.6 million (+16.3) Q2 2024 Net product sales for Tyvaso DPI were $258.3 million (+30.8) Q1 2024